journal article·2026-06-01Open access

Characterization of a hybrid hydrogel for the studying of lymphocyte infiltration and migration in a 3-dimensional in vitro tumor stroma device

Marco A Rodriguez, Saeed Derakhshesh, Mejalaa Mega Jayaseelan, Johan H Rosgaard, Alex Poh, Gennaro Longobardo, Thomas J DePalma, Aleksander Skardal

Biofabrication· Volume 18· Issue 2

Abstract

Abstract Solid tumors reprogram their surrounding microenvironment to develop a tumor promoting and immunosuppressive niche of cells and extracellular matrix known as the tumor stroma. While many successful immunotherapies modulating the use of cytotoxic lymphocytes have been established, success in solid tumors has been limited, in part due to the stroma disrupting T cell infiltration and/or migration into the tumor boundary, thereby obstructing their contact with cancer cells. There exists a need for the development of three-dimensional (3D) tissue engineered models to better understand the mechanisms of infiltration and migration of solid tumors by cytotoxic lymphocytes. Here we present the validation of a 3D hydrogel system, implemented into a tumor-on-a-chip device, allowing for the observation of infiltration and migration of T cells, in addition to the influence that tumor cells have on stromal fibroblasts. This hydrogel allows for greater infiltration of T cells compared to other formulations. Differences in migration are observed depending on lymphocyte type. Fibroblasts are influenced towards a cancer-associated fibroblast morphology with increased alpha-smooth muscle actin expression, and are seen to modify their spatial orientation relative to A375 melanoma cells. Finally fibroblast presence in the hydrogel inhibits infiltration of T cells. Combined, these results validate the application of this model to study lymphocyte infiltration and migration into solid tumors. Future modulation of cell populations, along with the integration of patient derived samples, can provide a system to test immunotherapy effectiveness for cancer patients.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: 3D Printing in Biomedical Research · Cancer Cells and Metastasis · CAR-T cell therapy research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (72)

Show source-provided references
1. Cancer statistics, 202510.3322/caac.21871 ↗
2. The tumor microenvironment10.1016/j.cub.2020.06.081 ↗
3. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments10.1186/s12943-023-01744-8 ↗
4. Epidemiology of melanoma10.3390/medsci9040063 ↗
5. Breast cancer metastasis: mechanisms and therapeutic implications10.3390/ijms23126806 ↗
6. Cancer metastasis: issues and challenges10.1186/s40880-017-0206-7 ↗
7. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways10.1038/s41571-021-00552-7 ↗
8. Emerging immunotherapies for metastasis10.1038/s41416-020-01160-5 ↗
9. Current status of immunotherapy in metastatic colorectal cancer10.1007/s00384-018-3202-8 ↗
10. Moving beyond cytotoxicity in cancer immunotherapy: embracing tumor microenvironment remodeling for durable control10.1038/s41416-025-03133-y ↗
11. Tumor microenvironment: implications in melanoma resistance to targeted therapy and immunotherapy10.3390/cancers12102870 ↗
12. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: treatment of melanoma and immune mechanisms of action10.1002/eji.202048747 ↗
13. Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future10.1158/1078-0432.Ccr-22-1922 ↗
14. Chimeric antigen receptor (CAR) T cell therapy for metastatic melanoma: challenges and road ahead10.3390/cells10061450 ↗
15. Rotte · 2016 · 419
16. Strategies for improving the efficacy of CAR T cells in solid cancers10.3390/cancers14030571 ↗
17. CAR T cell therapy for solid tumors10.1146/annurev-med-062315-120245 ↗
18. T-cell infiltration and its regulatory mechanisms in cancers: insights at single-cell resolution10.1186/s13046-024-02960-w ↗
19. Current advances and challenges in CAR T-cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment10.1186/s40164-023-00373-7 ↗
20. Immune checkpoint inhibitors in melanoma10.1016/S0140-6736(21)01206-X ↗
21. Decoding melanoma development and progression: identification of therapeutic vulnerabilities10.3389/fonc.2020.626129 ↗
22. Melanoma models for the next generation of therapies10.1016/j.ccell.2021.01.011 ↗
23. Current state of animal (mouse) modeling in melanoma research10.4137/cgm.S21214 ↗
24. Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models10.1016/j.annonc.2019.11.002 ↗
25. Mouse tumor models for advanced cancer immunotherapy10.3390/ijms21114118 ↗
26. Role of the tumor microenvironment in malignant melanoma organoids during the development and metastasis of tumors10.3389/fcell.2023.1166916 ↗
27. In vitro three-dimensional (3D) models for melanoma immunotherapy10.3390/cancers15245779 ↗
28. Human melanoma skin cancer models: a step towards drug testing & target therapy10.1007/s12015-025-10870-3 ↗
29. Fiji: an open-source platform for biological-image analysis10.1038/nmeth.2019 ↗
30. Efficient and optimized identification of generalized Maxwell viscoelastic relaxation spectra10.1016/j.jmbbm.2015.10.008 ↗
31. Computational segmentation of collagen fibers from second-harmonic generation images of breast cancer10.1117/1.JBO.19.1.016007 ↗
32. Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications10.1080/17425247.2016.1182485 ↗
33. Engineering Poly(ethylene glycol) particles for improved biodistribution10.1021/nn5061578 ↗
34. Thiol–maleimide “click” chemistry: evaluating the influence of solvent, initiator, and thiol on the reaction mechanism, kinetics, and selectivity10.1039/C5PY00168D ↗
35. Control of thiol-maleimide reaction kinetics in PEG hydrogel networks10.1016/j.actbio.2018.01.043 ↗
36. T cell morphodynamics reveal periodic shape oscillations in three-dimensional migration10.1098/rsif.2022.0081 ↗
37. Immunotherapy of melanoma10.5114/wo.2018.73889 ↗
38. Immunotherapy of melanoma: facts and hopes10.1158/1078-0432.Ccr-18-1550 ↗
39. Immunotherapy in melanoma: recent advances and future directions10.3390/cancers15041106 ↗
40. Stromal cells present in the melanoma niche affect tumor invasiveness and its resistance to therapy10.3390/ijms22020529 ↗
41. Stromal cells in the tumor microenvironment: accomplices of tumor progression?10.1038/s41419-023-06110-6 ↗
42. Cancer-associated fibroblasts and T cells: from mechanisms to outcomes10.4049/jimmunol.2001203 ↗
43. Cancer-associated fibroblasts suppress CD8+ T-cell infiltration and confer resistance to immune-checkpoint blockade10.1158/0008-5472.Can-21-4141 ↗
44. The therapeutic potential of resveratrol in a mouse model of melanoma lung metastasis10.1016/j.intimp.2020.106905 ↗
45. Primary melanoma characteristics of metastatic disease: a nationwide cancer registry study10.3390/cancers13174431 ↗
46. Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma10.3389/fimmu.2020.02105 ↗
47. Comprehensive analysis of the tumor microenvironment in cutaneous melanoma associated with immune infiltration10.7150/jca.44413 ↗
48. The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: a systematic review and meta-analysis10.1016/j.eclinm.2021.101134 ↗
49. CD8+ cytotoxic T lymphocytes in cancer immunotherapy: a review10.1002/jcp.27782 ↗
50. Exploring the NK cell platform for cancer immunotherapy10.1038/s41571-020-0426-7 ↗
51. Elucidation of focal adhesion kinase as a modulator of migration and invasion and as a potential therapeutic target in chronic lymphocytic leukemia10.3390/cancers14071600 ↗
52. Epstein–Barr virus induces aberrant B cell migration and diapedesis via FAK-dependent chemotaxis pathways10.1038/s41467-025-59813-z ↗
53. Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells10.1016/j.jneuroim.2005.02.001 ↗
54. MMP-9 inhibition promotes anti-tumor immunity through disruption of biochemical and physical barriers to T-cell trafficking to tumors10.1371/journal.pone.0207255 ↗
55. Fibroblast activation in cancer: when seed fertilizes soil10.1007/s00441-016-2467-x ↗
56. Melanoma cells with diverse invasive potential differentially induce the activation of normal human fibroblasts10.1186/s12964-022-00871-x ↗
57. A microfluidic blood brain barrier model to study the influence of glioblastoma tumor cells on BBB function10.1002/smll.202411361 ↗
58. Tuning a bioengineered hydrogel for studying astrocyte reactivity in glioblastoma10.1016/j.actbio.2024.09.048 ↗
59. Optimization of collagen type I-hyaluronan hybrid bioink for 3D bioprinted liver microenvironments10.1088/1758-5090/aae543 ↗
60. Vitronectin in human hepatic tumours contributes to the recruitment of lymphocytes in an αvβ3-independent manner10.1038/sj.bjc.6603467 ↗
61. The cancer genome atlas pan-cancer analysis project10.1038/ng.2764 ↗
62. Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR410.1002/eji.200526208 ↗
63. Collagen organization does not influence T-cell distribution in stroma of human pancreatic cancer10.3390/cancers13153648 ↗
64. The role of chemokines and extracellular matrix components in the migration of T lymphocytes into three-dimensional substrata10.1111/j.1365-2567.2004.02005.x ↗
65. Mitigating reactive oxygen species production and increasing gel porosity improves lymphocyte motility and fibroblast spreading in photocrosslinked gelatin-thiol hydrogels10.1101/2024.01.14.574282 ↗
66. Protein-protein association in polymer solutions: from dilute to semidilute to concentrated10.1529/biophysj.106.097717 ↗
67. Purinergic P2X4 receptors and mitochondrial ATP production regulate T cell migration10.1172/JCI120972 ↗
68. Targeting the microtubule-network rescues CTL killing efficiency in dense 3D matrices10.3389/fimmu.2021.729820 ↗
69. How molecular crowding differs from macromolecular crowding: a femtosecond mid-infrared pump–probe study10.1021/acs.jpclett.8b03153 ↗
70. Interactions between cancer-associated fibroblasts and T-cells: functional crosstalk with targeting and biomarker potential10.48101/ujms.v129.10710 ↗
71. Crosstalk between T lymphocyte and extracellular matrix in tumor microenvironment10.3389/fimmu.2024.1340702 ↗
72. The solid tumor microenvironment—breaking the barrier for T cells10.1002/bies.202100285 ↗